It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Extracellular vesicles (EVs) are lipid-membrane enclosed structures that are associated with several diseases, including those of genitourinary tract. Urine contains EVs derived from urinary tract cells. Owing to its non-invasive collection, urine represents a promising source of biomarkers for genitourinary disorders, including cancer. The most used method for urinary EVs separation is differential ultracentrifugation (UC), but current protocols lead to a significant loss of EVs hampering its efficiency. Moreover, UC protocols are labor-intensive, further limiting clinical application. Herein, we sought to optimize an UC protocol, reducing the time spent and improving small EVs (SEVs) yield. By testing different ultracentrifugation times at 200,000g to pellet SEVs, we found that 48 min and 60 min enabled increased SEVs recovery compared to 25 min. A step for pelleting large EVs (LEVs) was also evaluated and compared with filtering of the urine supernatant. We found that urine supernatant filtering resulted in a 1.7-fold increase on SEVs recovery, whereas washing steps resulted in a 0.5 fold-decrease on SEVs yield. Globally, the optimized UC protocol was shown to be more time efficient, recovering higher numbers of SEVs than Exoquick-TC (EXO). Furthermore, the optimized UC protocol preserved RNA quality and quantity, while reducing SEVs separation time.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7)
2 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); University of Porto, INEGI-LAETA, Faculty of Engineering, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226)
3 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); IMP Diagnostics, Praça do Bom Sucesso, Porto, Portugal (GRID:grid.435544.7); ICBAS-School of Medicine and Biomedical Sciences-University of Porto, Doctoral Programme in Medical Sciences, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226)
4 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); Universidade do Porto, i3S-Instituto de Investigação e Inovação em Saúde, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226); University of Porto, Doctoral Programme in Biomedical Sciences, ICBAS-School Medicine and Biomedical Sciences, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226)
5 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); University of Porto, Doctoral Programme in Biomedical Sciences, ICBAS-School Medicine and Biomedical Sciences, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226)
6 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); University of Porto, Doctoral Programme in Biomedical Sciences, ICBAS-School Medicine and Biomedical Sciences, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226); University Clinical Hospital of Santiago (CHUS/SERGAS), Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945)
7 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); Portuguese Oncology Institute of Porto (IPO Porto), Department of Pathology, Porto, Portugal (GRID:grid.435544.7)
8 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); Portuguese Oncology Institute of Porto (IPOPorto), Department of Urology, Porto, Portugal (GRID:grid.418711.a) (ISNI:0000 0004 0631 0608)
9 University Medical Center Rotterdam, Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands (GRID:grid.508717.c) (ISNI:0000 0004 0637 3764)
10 Universidade do Porto, i3S-Instituto de Investigação e Inovação em Saúde, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226); University of Porto, Cancer Drug Resistance Group, IPATIMUP-Institute of Molecular Pathology and Immunology, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226); University of Porto, Department of Biological Sciences, FFUP-Faculty of Pharmacy, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226)
11 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); Portuguese Oncology Institute of Porto (IPO Porto), Department of Pathology, Porto, Portugal (GRID:grid.435544.7); University of Porto (ICBAS-UP), Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226)
12 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); University of Porto (ICBAS-UP), Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226)